

IMPACT OF ADJUVANT THERAPY AFTER NEOADJUVANT THERAPY - IN PRACTICE

Jamie E. Chaft, MD - MSKCC

@ChaftJamie

April 20, 2024

Endorsed by



Accredited by



Presented by




CheckMate-816: Only Pre-op Tx


Key eligibility criteria

- Newly diagnosed, resectable, Stage IB (≥4 cm)–IIIA NSCLC (per AJCC TNM 7th edition)
- ECOG PS 0–1
- No known sensitizing *EGFR* mutations or *ALK* alterations

Stratified by stage (IB–II vs IIIA), PD-L1^a (≥1% vs <1%^b), and sex



EFS




Girard N, et al. Oral presentation at: ELCC 2023; 29 March–1 April 2023; Copenhagen, Denmark. Abstract 840


CheckMate-816: pCR by PD-L1



PD-L1 \geq 1%



PD-L1 < 1%





Provencio, et al. ESMO 2023.

CheckMate-816: pCR after neoadjuvant chemo +/- IO


3 year outcomes by pCR status

90% 3-year EFS

>95% 3-year OS



Girard N, et al. Oral presentation at: ELCC 2023; 29 March–1 April 2023; Copenhagen, Denmark. Abstract 840



So we gave induction therapy, now what?

Endorsed by





CheckMate-816: Lack of pCR after neoadjuvant chemo +/-IO

3 year outcomes by pCR status

<50% 3-year EFS rate


>75% 3-year OS



Girard N, et al. Oral presentation at: ELCC 2023; 29 March–1 April 2023; Copenhagen, Denmark. Abstract 840

Periop Trials


Keynote 671




- Stratification Factors**
- Disease stage (II vs III)
 - PD-L1 TPS^a (<50% vs ≥50%)
 - Histology (squamous vs nonsquamous)
 - Geographic region (east Asia vs not east Asia)

- Dual primary end points:** EFS per investigator review and OS
- Key secondary end points:** mPR and pCR per blinded, independent pathology review, and safety

Checkmate 77T




AEGEAN



Periop Trials: EFS


Keynote 671

Wakelee, H. (2023). *NEJM*, 389 (6), 491-503.




Checkmate 77T


Cascone, T. ESMO 2023.



AEGEAN

Heymach, J. V. (2023). *NEJM* 389 (18), 1672-1684.





Adjuvant IO after neoadjuvant chemo-IO: Is it feasible?

Trial	Start IO	Completed IO	
Keynote 671 ¹	pembrolizumab	73%	48%
AEGEAN ²	durvalumab	66%	Not mature
Checkmate 77T ³	nivolumab	62%	Not mature
NEOTORCH ⁴	torpalimab	71%	NR
(Rationale-315) ⁵	tislelizumab	74%	52%

¹Wakelee H, et al. NEJM



²Heymach J, et al. NEJM

³Cascone T, et al. ESMO 2023

⁴Lu S, et al. JAMA. 2024;331(3):201-1

⁵Yue D. et al. EMSO Virtual Plenary 2024


Periop vs Preop: Doesn't look that different at a quick glance




¹Wakelee H, et al. NEJM

²Cascone T, et al. ESMO 2023

Adjuvant IO after neoadjuvant chemo-IO: perhaps some legs in PD-L1 neg group



KN671 - outcomes by pCR status



CM77T - outcomes by pCR status


¹Wakelee H, et al. NEJM


²Cascone T, et al. ESMO 2023

Do we need IO after neoadjuvant chemo-IO?

We don't know...

- No comparative studies
- CM816 looks a lot like the periop studies
- 1 year of adj therapy: added risks, added cost, life/work interruptions





**We're doing better,
but we aren't curing enough
patients...
what's next for patients without
pCR from induction chemo-IO?**

Endorsed by

